UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc’s blockbuster drug, Humira, in reducing the severity of the disease. UCB’s drug, bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company. AbbVie’s Humira is the world’s top selling drug and treats rheumatoid arthritis and psoriasis. …read more
Source:: Yahoo Finance
